Format

Send to

Choose Destination
J Thromb Thrombolysis. 2008 Oct;26(2):85-90. doi: 10.1007/s11239-008-0258-2. Epub 2008 Jul 18.

Primary percutaneous coronary intervention for ST-elevation myocardial infarction using an intravenous and subcutaneous enoxaparin low molecular weight heparin regimen.

Author information

1
Division of Cardiology, Newark Beth Israel Medical Center, Newark, NJ, 07112, USA.

Abstract

BACKGROUND:

Enoxaparin use in PCI has been investigated, however its role in primary PCI is less known.

OBJECTIVE:

To evaluate the role of combination IV + SC enoxaparin in primary PCI in STEMI.

METHODS:

83 consecutive patients with STEMI who underwent primary PCI between January 1, 2005 and January 15, 2008 were included. Anticoagulation was based on our institution's STEMI protocol; either IV + SC enoxaparin, or IV unfractionated heparin (UFH). Clinical endpoints included MACE, bleeding and net adverse cardiac events (NACE).

RESULTS:

45 patients received UFH and 37 received IV + SC enoxaparin. There was no difference in the rate of mortality, MACE, or NACE. There was a trend toward more TIMI major and GUSTO moderate and severe bleeding in the UFH group.

CONCLUSIONS:

Application of IV + SC enoxaparin strategy for primary PCI in STEMI appears both safe and efficacious. A prospective randomized trial will be necessary to evaluate the safety and efficacy more thoroughly.

PMID:
18636227
DOI:
10.1007/s11239-008-0258-2
[Indexed for MEDLINE]

Supplemental Content

Full text links

Icon for Springer
Loading ...
Support Center